Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
46,611,135
-
Shares change
-
+7,776,825
-
Total reported value, excl. options
-
$90,890,151
-
Value change
-
+$6,156,453
-
Put/Call ratio
-
1686%
-
Number of buys
-
37
-
Number of sells
-
27
-
Price
-
$1.95
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q1 2023
As of 31 Mar 2023 ADC Therapeutics SA - Common Shares (ADCT) had 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 46,611,135 shares of stock of the company.
Largest 10 holders included Redmile Group, LLC, CITADEL ADVISORS LLC, Prosight Management, LP, JPMORGAN CHASE & CO, GOLDMAN SACHS GROUP INC, Sio Capital Management, LLC, MILLENNIUM MANAGEMENT LLC, EVENTIDE ASSET MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., and BANK OF AMERICA CORP /DE/.
This table shows 57 institutional shareholders of the security as of 31 Mar 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.